Marchex - MCHX Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marchex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MCHX shares.
View MCHX analyst ratings or view top-rated stocks.

1 analysts have issued 12 month price objectives for Marchex's shares. Their MCHX share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 94.2% from the stock's current price.
View analysts price targets for MCHX or view top-rated stocks among Wall Street analysts.

Marchex's stock was trading at $2.48 at the beginning of 2022. Since then, MCHX stock has decreased by 16.9% and is now trading at $2.06.
View the best growth stocks for 2022 here.

Marchex is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our MCHX earnings forecast.

Marchex will be holding an earnings conference call on Tuesday, August 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Marchex, Inc. (NASDAQ:MCHX) issued its quarterly earnings data on Thursday, May, 12th. The technology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02. The technology company earned $13.17 million during the quarter, compared to analyst estimates of $13.04 million. Marchex had a negative net margin of 1.19% and a negative trailing twelve-month return on equity of 8.11%. During the same quarter in the previous year, the firm posted ($0.10) EPS.

8 employees have rated Marchex Chief Executive Officer Russell Horowitz, Michael Arends, and Ethan Caldwell. on Glassdoor.com. Russell Horowitz, Michael Arends, and Ethan Caldwell. has an approval rating of 58% among the company's employees. This puts Russell Horowitz, Michael Arends, and Ethan Caldwell. in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marchex investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Enphase Energy (ENPH), NVIDIA (NVDA), OPKO Health (OPK), Nokia Oyj (NOK), Overstock.com (OSTK), Block (SQ) and Zynga (ZNGA).

Marchex trades on the NASDAQ under the ticker symbol "MCHX."

Shares of MCHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCHX stock can currently be purchased for approximately $2.06.

Marchex (NASDAQ:MCHX) has a market capitalization of $87.17 million and generates $53.48 million in revenue each year. The technology company earns $-4,390,000.00 in net income (profit) each year or ($0.02) on an earnings per share basis.

Marchex employs 187 workers across the globe.

Marchex was founded in 2003.

Marchex's mailing address is 520 PIKE STREET SUITE 2000, SEATTLE WA, 98101. The official website for the company is www.marchex.com. The technology company can be reached via phone at (206) 331-3300, via email at ir@marchex.com, or via fax at 206-331-3695.